Tonix Pharmaceuticals Presents Lyme & Mpox Vaccine Data at World Vaccine Congress 2026
WASHINGTON, D.C. – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced today it will present data on its Lyme disease and mpox vaccine candidates at the World Vaccine Congress Washington 2026, being held in the nation’s capital from March 30 through April 2. The presentations will cover Phase 1 data for TNX-4800, a monoclonal antibody designed for Lyme disease prevention, and preclinical findings for TNX-801, a vaccine targeting mpox and smallpox.
The company’s research will be presented in a series of talks and a moderated panel discussion. Mark S. Klempner, MD, Professor of Medicine at UMass Chan Medical School and inventor of TNX-4800, will present Phase 1 data on the Lyme disease antibody on Monday, March 30, at 10:10 a.m. ET in Room 202B. The presentation, titled “A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease,” falls under the “Measuring Breadth & Emerging Targets” session category.
TNX-4800 is a fully human monoclonal antibody that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease. According to Tonix, the antibody is designed to kill and block the maturation of the bacteria within ticks, potentially providing pre-exposure prophylaxis against Lyme disease without relying on the recipient’s immune system. Published animal studies have shown the antibody to be 95% effective in preventing infection after a six-day exposure to infected ticks.
On Wednesday, April 1, Farooq Nasar, PhD, Director of Virology at Tonix, will present data on TNX-801, a live attenuated horsepox virus vaccine candidate, at 10:10 a.m. ET in Room 202A. The presentation, titled “A Live Attenuated, Minimally Replicative MPOX Vaccine,” is part of the “Emerging & Re-Emerging Diseases” session. Later that day, at 3:25 p.m. ET in Room 20A, Christopher Cooper, PhD, Director of Immunology at Tonix, will moderate a panel discussion on “Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity,” also within the “Emerging & Re-Emerging Diseases” category.
Tonix acquired TNX-4800 from UMass Chan Medical School in 2025. Phase 1 trials, conducted in 44 randomized subjects (41 completed), evaluated the safety, tolerability, pharmacokinetics, and immunogenicity of the antibody. Results indicated rapid systemic absorption and quantifiable antibody concentrations lasting for over 200 days in 80% of volunteers at the lowest dose, and up to 350 days in most volunteers at higher doses. The company anticipates having GMP investigational product available for clinical testing in early 2027, with a potential field study enrollment in the first half of 2027 and a controlled human infection model (CHIM) study in 2028, pending FDA clearances.
Lyme disease, the most common vector-borne infection in the United States, is increasingly prevalent due to expanding tick habitats linked to climate change. Symptoms include fever, headache, fatigue, and a characteristic skin rash. Untreated infections can spread to joints, the heart, and the nervous system. The National Academies of Sciences, Engineering, and Medicine recently published a report charting a path toward new treatments for Lyme Infection-Associated Chronic Illnesses (IACI).